← FDA DRUG APPROVALS

FDA ANDA · ANDA207081

CYRED EQ

desogestrel and ethinyl estradiol

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA207081
TYPE
ANDA
ORIGINAL APPROVAL
2017-05-17
LATEST ACTION
2022-04-29
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

KALLIGAPrescription
DESOGESTREL 0.15MG, ETHINYL ESTRADIOL 0.03MG · TABLET · ORAL-28

Approval history

2022-04-29Labeling · Supplement 4 · standardAP
2019-10-28Labeling · Supplement 1 · standardAP
2017-05-17UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →